13-Feb-2026
No headlines found.
No press releases found.
No news found.
Virtus LifeSci Biotech Clinical Trials ETF is an exchange-traded fund incorporated in the USA. The Fund seeks investment results that correspond to the performance of the LifeSci Biotechnology Clinical Trials Index. Clinical Trials stage companies are typically younger, smaller companies which do not have a drug approved, but instead focus on testing their experimental drugs.
Virtus Lifesci Biotech Clinical Trials ETF trades on the ARCA stock market under the symbol BBC.
As of February 13, 2026, BBC stock price declined to $39.87 with 13,932 million shares trading.
BBC has a beta of 1.33, meaning it tends to be more sensitive to market movements. BBC has a correlation of 0.30 to the broad based SPY ETF.
BBC has a market cap of $33.89 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BBC traded as high as $44.10 and as low as $13.42.
BBC has outperformed the market in the last year with a return of +85.3%, while the SPY ETF gained +13.0%. In the last 3 month period, BBC beat the market returning +28.8%, while SPY returned +1.7%. However, in the most recent 2 weeks BBC has underperformed the stock market by returning -2.4%, while SPY returned -1.5%.
BBC support price is $39.17 and resistance is $41.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBC shares will trade within this expected range on the day.
